Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level652 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,842 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00439608 | Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer | completed | Phase 2 | 60 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 34 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01516944 | Perioperative Chemotherapy for Potentially Resectable Gastric Cancer | completed | Phase 2 / Phase 3 | 749 | Hebei Medical UniversityOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00525785 | Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) | completed | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01747551 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | completed | Phase 2 | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT00565370 | Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP | completed | Phase 1 / Phase 2 | 22 | Asan Medical CenterOTHER | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00398398 | Study of XELOX With Cetuximab in Advanced Gastric Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT00976768 | Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01045538 | Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | completed | Phase 1 / Phase 2 | 45 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01187212 | Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE | completed | Phase 2 | 195 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01471470 | Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01719549 | Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1 | completed | Phase 2 | 19 | Asan Medical CenterOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT02451956 | Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | completed | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT00515411 | Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 111 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02204306 | Genotype Guided Chemotherapy in Gastric Cancer Patients | completed | Phase 2 | 330 | Central South UniversityOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01983878 | A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 36 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 30, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01743365 | Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer(A-GAPP) | completed | Phase 2 | 55 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02999295 | A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer | completed | Phase 1 / Phase 2 | 46 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01216644 | 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer | completed | Phase 2 / Phase 3 | 716 | Krankenhaus NordwestOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01132755 | Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage | completed | Phase 2 | 112 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT00601705 | Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach | completed | Phase 2 | 61 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01514110 | Gastric Cancer RAD001 Study | completed | Phase 1 / Phase 2 | 35 | Chinese University of Hong KongOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT00217581 | Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 39 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT01715233 | Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer. | completed | Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT00711243 | Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor | completed | Phase 1 / Phase 2 | 59 | Northwestern UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT01129310 | First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.(IXOGoo1) | completed | Phase 2 | 47 | AHS Cancer Control AlbertaOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT01503372 | FLO +/- Pazopanib as First-line Treatment in Advanced Gastric Cancer(PaFLO) | completed | Phase 2 | 75 | Charite University, Berlin, GermanyOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03350477 | Bioinformation Therapy for Gastric Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT00215644 | Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer(MATRIX EG) | completed | Phase 2 | 72 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Nov 2, 2018 | clinicaltrials |
| NCT00137813 | Avastin and Taxotere for Esophagogastric Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00019474 | Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer | completed | Phase 2 | 60 | Montefiore Medical CenterOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT00607594 | Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Aug 23, 2018 | clinicaltrials |
| NCT01461057 | A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Advanced Gastric Cancer(JOSHUA) | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 8 | Aug 9, 2018 | clinicaltrials |
| NCT01783951 | Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer | completed | Phase 1 / Phase 2 | 63 | Capital Medical UniversityOTHER | 1 | Jul 19, 2018 | clinicaltrials |
| NCT00068380 | A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01956149 | Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer | completed | Phase 2 | 65 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01757171 | Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma | completed | Phase 2 | 85 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00938470 | Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction | completed | Phase 2 | 73 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT00183872 | Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma | completed | Phase 2 | 40 | University of Southern CaliforniaOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01612546 | Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery | completed | Phase 2 | 10 | City of Hope Medical CenterOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT01178944 | Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00201747 | Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer | completed | Phase 2 | 80 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00394433 | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | completed | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02229058 | Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer | completed | Phase 2 | 73 | Sun Yat-sen UniversityOTHER | 1 | Jul 27, 2017 | clinicaltrials |
| NCT01921673 | Dovitinib Plus Docetaxel in Gastric Cancer | completed | Phase 1 / Phase 2 | 14 | Asan Medical CenterOTHER | 1 | Jul 14, 2017 | clinicaltrials |
| NCT00062374 | Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 6, 2017 | clinicaltrials |
| NCT01472029 | Explorative Phase II Study of Perioperative Treatment in Patients With Adenocarcinoma of the Gastroesophageal Junction or Stomach(HerFLOT) | completed | Phase 2 | 53 | AIO-Studien-gGmbHOTHER | 1 | Jun 19, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Feb 17, 2020source: clinicaltrials